Blueprint
 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of September 2017
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
26 September 2017 12:00 BST
 
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announces that, on 25 September 2017, an award of the Company's American Depositary Shares (ADSs) made under the AstraZeneca Restricted Share Plan (AZRSP) vested to Sean Bohen, a person discharging managerial responsibilities (PDMR) of the Company. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.
 
The AZRSP award was granted on 25 September 2015 and vested in two tranches on the first and second anniversaries of grant. Following the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Bohen became beneficially entitled to and received 12,385 ADSs.
 
For tax purposes, the fair market value of an ADS at vest was $33.95, being the closing price on the last trading day preceding the vesting day.
 
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation.
 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 
Media Relations
 
 
Esra Erkal-Paler
UK/Global
+44 203 749 5638
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Matt Kent
UK/Global
+44 203 749 5906
Jacob Lund
Sweden
+46 8 553 260 20
Michele Meixell
US
+1 302 885 2677
 
 
 
Investor Relations
 
 
Thomas Kudsk Larsen
 
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Christer Gruvris
Diabetes; Autoimmunity, Neuroscience & Infection
+44 203 749 5711
Nick Stone
Respiratory; Brilinta
+44 203 749 5716
US toll free
 
+1 866 381 7277
 
 
Adrian Kemp
Company Secretary, AstraZeneca PLC
 
 
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
a)
 
Name
Sean Bohen
2
 
Reason for the notification
 
a)
 
Position/status
 
Person discharging managerial responsibilities
b)
 
Initial notification /Amendment
Initial notification
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
AstraZeneca PLC
b)
 
LEI
PY6ZZQWO2IZFZC3IOL08
4i
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
 
Description of the financial instrument, type of instrument
 
Identification code
 
AstraZeneca PLC American Depositary Shares
 
  
CUSIP: 046353108
b)
 
Nature of the transaction
 
 
Acquisition of ADSs pursuant to vesting under the AstraZeneca Restricted Share Plan, for nil consideration.
c)
 
Price(s) and volume(s)
 
Price(s) 
 Volume(s)
 
 
0
 12,385
d)
 
Aggregated information
 
- Aggregated volume
- Price
 
Not applicable - single transaction
e)
 
Date of the transaction
 
25 September 2017
f)
 
Place of the transaction
 
Outside a trading venue
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 26th September 2017
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary